Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma

Cancer

Volumn 117, Issue 12, 2011, Pages 2677-2689

  Van Tubergen, Elizabeth ^a   Vander Broek, Robert ^a   Lee, Julia ^b   Wolf, Gregory ^c   Carey, Thomas ^c   Bradford, Carol ^c   Prince, Mark ^c   Kirkwood, Keith L ^d   D'Silva, Nisha J ^a,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

cytokines; interleukin 6 (IL 6); messenger RNA (mRNA) stability; prostaglandin E2 (PGE2); vascular endothelial growth factor (VEGF)

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROSTAGLANDIN E2; TRISTETRAPROLIN; VASCULOTROPIN;

ADENOVIRUS 5; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INDUCTION; ENZYME REGULATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA STABILITY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR RECURRENCE;

CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-6; NEOPLASM INVASIVENESS; NEOPLASMS, SQUAMOUS CELL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA STABILITY; TRISTETRAPROLIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958852872     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25859     Document Type: Article

References (52)

1. Aggarwal BB, Gehlot P., Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009; 9: 351-369.
2. Dong G, Loukinova E, Smith CW, Chen Z, Van Waes C., Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. J Cell Biochem Suppl. 1997; 28-29: 90-100. (Pubitemid 28246632)
3. Kanazawa T, Nishino H, Hasegawa M, et al. Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol. 2007; 264: 815-821. (Pubitemid 46817497)
4. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999; 5: 1369-1379. (Pubitemid 29282941)
5. Pries R, Nitsch S, Wollenberg B., Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2006; 6: 1195-1203.
6. Pries R, Wollenberg B., Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006; 17: 141-146. (Pubitemid 43949076)
7. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A., COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005; 26: 1393-1399.
8. Tsujii M, Kawano S, DuBois RN., Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997; 94: 3336-3340. (Pubitemid 27157312)
9. Anderson P., Post-transcriptional control of cytokine production. Nat Immunol. 2008; 9: 353-359. (Pubitemid 351405104)
10. Audic Y, Hartley RS., Post-transcriptional regulation in cancer. Biol Cell. 2004; 96: 479-498.
11. Carrick DM, Blackshear PJ., Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Arch Biochem Biophys. 2007; 462: 278-285. (Pubitemid 46856329)
12. Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM., The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res. 2009; 69: 5168-5176.
13. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA., The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology. 2009; 136: 1669-1679.
14. Parkin DM, Bray F, Ferlay J, Pisani P., Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94: 153-156. (Pubitemid 32911406)
15. Riebe C, Pries R, Kemkers A, Wollenberg B., Increased cytokine secretion in head and neck cancer upon p38 mitogen-activated protein kinase activation. Int J Mol Med. 2007; 20: 883-887.
16. Nystrom ML, McCulloch D, Weinreb PH, et al. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res. 2006; 66: 10833-10842. (Pubitemid 44876979)
17. Peters WH, Lacko M, Te Morsche RH, Voogd AC, Oude Ophuis MB, Manni JJ., COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck. 2009; 31: 938-943.
18. Sappayatosok K, Maneerat Y, Swasdison S, et al. Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in oral squamous cell carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation. Med Oral Patol Oral Cir Bucal. 2009; 14: E319-E324.
19. Kurihara Y, Hatori M, Ando Y, et al. Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis. 2009; 26: 425-432.
20. Egloff AM, Grandis JR., Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol. 2008; 35: 286-297. (Pubitemid 351787698)
21. Paul WE., Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell. 1989; 57: 521-524. (Pubitemid 19140639)
22. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006; 12: 5064-5073. (Pubitemid 44453332)
23. Mitra RS, Goto M, Lee JS, et al. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res. 2008; 68: 3959-3969.
24. Mitra RS, Zhang Z, Henson BS, Kurnit DM, Carey TE, D'Silva NJ., Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form. Oncogene. 2003; 22: 6243-6256. (Pubitemid 37281654)
25. Park NH, Min BM, Li SL, Huang MZ, Cherick HM, Doniger J., Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. Carcinogenesis. 1991; 12: 1627-1631.
26. Patil CS, Liu M, Zhao W, et al. Targeting mRNA stability arrests inflammatory bone loss. Mol Ther. 2008; 16: 1657-1664.
27. Henson BS, Neubig RR, Jang I, et al. Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem. 2005; 280: 22564-22571. (Pubitemid 40853159)
28. Goto M, Mitra RS, Liu M, et al. Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2010; 16: 65-76.
29. Gillenwater AM, Zhong M, Lotan R., Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther. 2007; 6: 2967-2975. (Pubitemid 350206775)
30. Wolf GT, Urba S, Hazuka M., Induction chemotherapy for organ preservation in advanced squamous cell carcinoma of the oral cavity and oropharynx. Recent Results Cancer Res. 1994; 134: 133-143.
31. Ng DC, Long CS, Bogoyevitch MA., A role for the extracellular signal-regulated kinase and p38 mitogen-activated protein kinases in interleukin-1 beta-stimulated delayed signal tranducer and activator of transcription 3 activation, atrial natriuretic factor expression, and cardiac myocyte morphology. J Biol Chem. 2001; 276: 29490-29498.
32. Heidenreich O, Neininger A, Schratt G, et al. MAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivo. J Biol Chem. 1999; 274: 14434-14443.
33. Winzen R, Kracht M, Ritter B, et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 1999; 18: 4969-4980. (Pubitemid 29443799)
34. Brosens LA, Keller JJ, Pohjola L, et al. Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther. 2008; 7: 424-427. (Pubitemid 351847061)
35. Levy AP, Levy NS, Goldberg MA., Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem. 1996; 271: 2746-2753. (Pubitemid 26047892)
36. Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003; 101: 703-705. (Pubitemid 36077596)
37. Druzgal CH, Chen Z, Yeh NT, et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2005; 27: 771-784. (Pubitemid 41266181)
38. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS., Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 1999; 59: 1592-1598. (Pubitemid 29160131)
39. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995; 86: 685-691.
40. Smith PC, Keller ET,. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate. 2001; 48: 47-53.
41. Anderson P,. Intrinsic mRNA stability helps compose the inflammatory symphony. Nat Immunol. 2009; 10: 233-234.
42. Stoecklin G, Stoeckle P, Lu M, Muehlemann O, Moroni C,. Cellular mutants define a common mRNA degradation pathway targeting cytokine AU-rich elements. RNA. 2001; 7: 1578-1588. (Pubitemid 33078933)
43. Taylor GA, Carballo E, Lee DM, et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 1996; 4: 445-454. (Pubitemid 26354654)
44. Lee HH, Son YJ, Lee WH, et al. Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer. Int J Cancer. 2010; 126: 1817-1827.
45. Al-Souhibani N, Al-Ahmadi W, Hesketh JE, Blackshear PJ, Khabar KS, The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. Oncogene. 2010; 29: 4205-4215.
46. Keller ET, Wanagat J, Ershler WB, Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci. 1996; 1: d340-d357.
47. Kishimoto T., Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005; 23: 1-21. (Pubitemid 40563163)
48. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008; 113: 750-757.
49. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S., The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer. 2005; 5: 42.
50. Suswam E, Li Y, Zhang X, et al. Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res. 2008; 68: 674-682. (Pubitemid 351206742)
51. Basu A, Datta D, Zurakowski D, Pal S., Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem. 2010; 285: 25196-25202.
52. Fantini MC, Becker C, Kiesslich R, Neurath MF., Drug insight: novel small molecules and drugs for immunosuppression. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 633-644. (Pubitemid 44644774)